World's First -- XellSmart's Allogeneic iPSC-derived Regenerative Cell Therapy for Spinal Cord Injury Officially Approved by the U.S. FDA for a Registrational Phase I Clinical Trial ...Middle East

SUZHOU, China, May 25, 2025 /PRNewswire/ -- In May 2025, XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. officially announced that XellSmart-developed off-the-shelf allogeneic iPSC-derived subtype-specific neural regenerative cell therapy has received official approval from both...

Hence then, the article about world s first xellsmart s allogeneic ipsc derived regenerative cell therapy for spinal cord injury officially approved by the u s fda for a registrational phase i clinical trial was published today ( Monday 26/05/2025 - 04:06 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( World's First -- XellSmart's Allogeneic iPSC-derived Regenerative Cell Therapy for Spinal Cord Injury Officially Approved by the U.S. FDA for a Registrational Phase I Clinical Trial )

Also on site :

• Lauren Chapin, the Youngest Kid on ‘Father Knows Best,’ Dies at 80
• Wynn Resorts faces second lawsuit after data breach incident involving employees
• Angel Reese Stuns With Daring Pregame Outfit